Cell Source Stock Today
| CLCS Stock | USD 0.88 -0.07 -7.37% |
Performance Balanced
| Odds Of Distress Low
|
As of March 18, 2026, Cell Source is priced at $0.88, reflecting a 7.37% decrease today after opening at $0.95. Current risk models assign Cell Source a 10% probability of financial distress, reflecting a relatively small probability within its capital structure. Risk-adjusted return data over the last 90 trading days classifies Cell Source as balanced in terms of performance. The performance scores are calculated from December 18, 2025 through March 18, 2026. Learn more.
Moving against Cell Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Pink Sheet Highlights
Cell Source [CLCS] is a Pink Sheet which is traded between brokers over the counter. The company conducts business in the Biotechnology industry (Healthcare sector). Cell Source carries a micro-cap market capitalization of 10.61 M when compared with biotechnology companies. Associated fundamentals relevant to market cap include a workforce of about 1 people, about 35.25 M shares outstanding, and operating in the Biotechnology industry. Net Loss for the year was -5.47 M with profit before overhead, payroll, taxes, and interest of 0. Cell Source financial stability analysis Ownership Allocation Cell Source carries a considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. The ownership breakdown for Cell Source shows approximately 0% institutional, 32% insider, and 68% public. Check Cell Ownership DetailsNotable Updates
| CEO | Itamar Shimrat |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Common Risk Profiles
| Mean Deviation | 4.43 | |||
| Semi Deviation | 3.75 | |||
| Standard Deviation | 6.35 | |||
| Variance | 40.38 |
Cell Source Against Markets
Pink Sheet Analysis Notes
About 32.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.2. Cell Source had not issued any dividends in recent years. Latest disclosures for Cell Source show $314 thousand in Total Assets and $214 thousand in Current Assets.Investor Insights and Alerts
| Cell Source is way too risky over 90 days horizon | |
| Cell Source has some characteristics of a very speculative penny stock | |
| Cell Source appears to be risky and price may revert if volatility continues | |
| Cell Source currently holds $6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was -5.47 M with profit before overhead, payroll, taxes, and interest of 0. | |
| Cell Source currently holds about 93.09 K in cash with -3.38 M of positive cash flow from operations. | |
| Roughly 32.0% of the company shares are held by company insiders |
Market Capitalization
Cell Source carries a micro-cap market capitalization of 10.61 M when compared with biotechnology companies. Associated fundamentals relevant to market cap include a workforce of about 1 people, about 35.25 M shares outstanding, and operating in the Biotechnology industry.Technical Drivers
As of the 18th of March 2026, the last recorded price for Cell Source is 0.88 per share. Primary technical drivers reflect Downside Deviation of 7.09, risk adjusted performance of 0.1512, and Mean Deviation of 4.43. Quantitative analysis incorporates volatility metrics and price behavior to assess directional bias. Below $1.00, price stability and volume dispersion are closely evaluated. Metrics are compared to industry averages to assess relative positioning.Cell Source Price Movement Analysis
Transformation |
This analysis covers sixty-one data points across the selected time horizon. Cell Source Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Cell Source price patterns.
Outstanding Bonds
Outstanding bonds linked to Cell Source can tell investors a great deal about how the company finances itself beyond common equity markets. Current market capitalization is about 10.61 Million. Bond investors and equity investors often care about the same cash flows, but they rank the risks differently.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| CELARA 3875 02 NOV 27 Corp BondUS151191BB89 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US15118JAA34 Corp BondUS15118JAA34 | View |
Predictive Daily Indicators
Short-horizon indicators in Cell Source turn fast-changing price action into clearer risk and execution cues. The best setups combine these signals with strict risk limits, since short-term data can reverse fast when liquidity thins.
Forecast Models
Quantitative tools for Cell Source focus on observed patterns, which helps when markets move faster than research can update. The practical edge is not the forecast number itself, but knowing when the data is becoming less predictable.Pink Sheet Overview, Methodology & Data Sources
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people. A high-level view of Cell Source emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Cell Source has a market cap of 10.61 M.
Methodology
Unless otherwise specified, financial data for Cell Source is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cell (USA Stocks:CLCS) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Cell Source may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardBe your own money manager
Portfolio optimization matters because investors need a repeatable way to decide whether adding Cell Source improves expected return without taking on disproportionate risk. A stronger allocation process asks what the position adds to the portfolio, not just what it might do on its own.
Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Additional Tools for Cell Pink Sheet Analysis
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |